within Pharmacolibrary.Drugs.ATC.A;

model A14AA09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 3.3333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A14AA09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Norethandrolone is a synthetic anabolic-androgenic steroid derived from 19-nortestosterone. It was formerly used to treat a variety of conditions including anemia and osteoporosis, but is not currently approved for use in most countries due to its side effect profile and potential for misuse.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed pharmacokinetic model with parameter values for norethandrolone in humans is available. The following are estimated values based on structural similarity to other 19-nortestosterone derivatives used orally, in a standard adult population.</p><h4>References</h4><ol><li><p>Sherlock, S (1968). Chronic cholangitides: aetiology, diagnosis, and treatment. <i>British medical journal</i> 3(5617) 515–521. DOI:<a href=&quot;https://doi.org/10.1136/bmj.3.5617.515&quot;>10.1136/bmj.3.5617.515</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4971054/&quot;>https://pubmed.ncbi.nlm.nih.gov/4971054</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A14AA09;
